Abstract
Preliminary Efficacy and Safety Data from the Phase 2 Trial of Riliprubart (SAR445088), a Humanized Monoclonal Antibody Targeting Complement C1s, in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (S15.008)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have